ZA964215B - Fatty acid treatment - Google Patents

Fatty acid treatment

Info

Publication number
ZA964215B
ZA964215B ZA964215A ZA964215A ZA964215B ZA 964215 B ZA964215 B ZA 964215B ZA 964215 A ZA964215 A ZA 964215A ZA 964215 A ZA964215 A ZA 964215A ZA 964215 B ZA964215 B ZA 964215B
Authority
ZA
South Africa
Prior art keywords
pct
fatty acid
acid treatment
sec
fatty acids
Prior art date
Application number
ZA964215A
Other languages
English (en)
Inventor
B Jacqueline Stordy
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of ZA964215B publication Critical patent/ZA964215B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
ZA964215A 1995-05-25 1996-05-24 Fatty acid treatment ZA964215B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9510636.5A GB9510636D0 (en) 1995-05-25 1995-05-25 Fatty acid treatment

Publications (1)

Publication Number Publication Date
ZA964215B true ZA964215B (en) 1996-12-04

Family

ID=10775045

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA964215A ZA964215B (en) 1995-05-25 1996-05-24 Fatty acid treatment

Country Status (16)

Country Link
US (1) US6150411A (de)
EP (1) EP0774962B1 (de)
JP (1) JPH10503531A (de)
KR (1) KR970704433A (de)
AT (1) ATE264676T1 (de)
AU (1) AU722474B2 (de)
CA (1) CA2195979A1 (de)
DE (1) DE69632236T2 (de)
DK (1) DK0774962T3 (de)
ES (1) ES2217317T3 (de)
FI (1) FI970298A0 (de)
GB (1) GB9510636D0 (de)
NO (1) NO970317D0 (de)
PT (1) PT774962E (de)
WO (1) WO1996037200A1 (de)
ZA (1) ZA964215B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1121115T4 (da) * 1998-10-15 2011-01-10 Dsm Ip Assets Bv PUFA-tilskud
KR100341109B1 (ko) * 1999-03-10 2002-06-20 이인수 인식력 및 기억력 증강용 식이 조성물
US7112609B2 (en) * 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
US6258846B1 (en) * 1999-06-01 2001-07-10 Drugtech Corporation Nutritional supplements
GB9918023D0 (en) 1999-07-30 1999-09-29 Unilever Plc Skin care composition
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
EP1417211B1 (de) 2001-07-27 2007-05-30 Neptune Technologies & Bioressources Inc. Flavonoide und mehrfach ungesättigte fettsäuren enthaltende natürliche phospholipide maritimen ursprungs sowie deren anwendungen
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
TWI365716B (en) * 2003-12-02 2012-06-11 Suntory Holdings Ltd Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same
EP1713463A4 (de) * 2004-01-19 2009-03-18 Martek Biosciences Corp Reelin-mangel oder dysfunktion und relevante verfahren
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0813599D0 (en) * 2008-07-24 2008-09-03 Pharma Marine As Method
NO2493478T3 (de) 2009-10-29 2018-07-21
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
MX379148B (es) * 2016-06-01 2025-03-10 Soc Des Produits Nestle S A Star Composición para usar en la profilaxis de enfermedades alérgicas.
WO2023102170A1 (en) * 2021-12-02 2023-06-08 The Regents Of The University Of California Compositions and methods for inhibiting seizures

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
EP0711503A3 (de) * 1994-11-14 1997-11-26 Scotia Holdings Plc Mit GLA und/oder DGLA angereicherte Milch

Also Published As

Publication number Publication date
PT774962E (pt) 2004-09-30
FI970298A7 (fi) 1997-01-24
WO1996037200A1 (en) 1996-11-28
EP0774962B1 (de) 2004-04-21
HK1012575A1 (en) 1999-08-06
DE69632236D1 (de) 2004-05-27
NO970317L (no) 1997-01-24
KR970704433A (ko) 1997-09-06
FI970298L (fi) 1997-01-24
FI970298A0 (fi) 1997-01-24
ATE264676T1 (de) 2004-05-15
ES2217317T3 (es) 2004-11-01
EP0774962A1 (de) 1997-05-28
DE69632236T2 (de) 2005-04-14
NO970317D0 (no) 1997-01-24
AU5827796A (en) 1996-12-11
AU722474B2 (en) 2000-08-03
GB9510636D0 (en) 1995-07-19
US6150411A (en) 2000-11-21
DK0774962T3 (da) 2004-08-09
JPH10503531A (ja) 1998-03-31
CA2195979A1 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
GB9510636D0 (en) Fatty acid treatment
GB9220667D0 (en) Improvements in or relating to dioic acids
HU9700056D0 (en) New pharmaceutical composition for treating pains
NO942351D0 (de)
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
ZA967626B (en) Lipid extract having anti-inflammatory activity.
NO971037L (no) Trifenyletylener til beskyttelse mot behandling av osteoporose
PT880350E (pt) Tratamento de esclerose multipla
PT920323E (pt) Nova utilizacao de fosfolipidos de origem animal em terapeutica e/ou dietetica
DK0770089T3 (da) Vækstdifferentieringsfaktor-12
ZA931318B (en) Method of treatment
KR910007858A (ko) 초기-촉진 및 향상된 진통제로서의 s(+)-이부프로펜-l-아미노산 및 s(+)-이부프로펜-d-아미노산
GB8714772D0 (en) Essential fatty acid compositions
NZ506681A (en) Disinfecting composition
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
EP1037918A4 (de) Verfahren und zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
ZA959377B (en) A storage stable water solution for infusion containing a thrombin inhibitor
ATE200624T1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
GB9304399D0 (en) Novel process
ZA949350B (en) Aqueous prolonged release formulation
DE59202373D1 (en) N-acyl-phosphatidylethanolamin als oxidationsschutzmittel.
UA29506C2 (uk) Лікувально-косметичний засіб "фіто-пелоїд"
AU1195497A (en) Use of alpha,alpha-diphenylacetic acid-4-(n-methyl-piperidyl)ester as anti-spasmodic